Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties.
Melina K GrasmeierSusanne WeberMatthias TreiberMarkus A ThalerPeter B LuppaPublished in: Clinical chemistry and laboratory medicine (2023)
Overall, both SPR biosensor assays exhibited reliable quantitative performance with accuracies superior to their ELISA counterparts and precision inferior to ELISA only for ADAmon. DissR presented itself as promising ADA binding parameter and could contribute to both earlier and more tailored therapeutic decisions.